


ITW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jörgen Carlsson, et al. Docket: 102821-202
Serial No.: 10/563,310 Art Unit:
Filed: December 29, 2005 Examiner:
Conf. No.: 6946 Customer No.: 27267
Title: POLYPEPTIDES HAVING BINDING AFFINITY FOR HER2

AMENDMENT TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an amendment in the above-identified application. The fees have been calculated as shown below:

12/07/2007 HDESTA1 00000033 231665 10563310
01 FC:2251 60.00 DA

CERTIFICATE OF MAILING OR TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being:

- ☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office via facsimile at (571) 273-8300.

Date: December 5, 2007

Signed: _____

E. A. Galletta
Elizabeth A. Galletta

1. Claim Fees

<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27							
Fee Description	Claims Remaining After Amendment	Minus	Highest Number Previously paid for	No. of extra claims present	Large Entity Fee (\$)	Small Entity Fee (\$)	Fees Paid (\$)
Each claim over 20 (incl. Reissues)		-20			\$50	\$25	
Each Independent claim over 3 (incl. Reissues)		-3			\$210	\$105	
Multiple Dependent Claims (if any)					\$370	\$185	\$0.00
TOTAL FEES PAID					\$0.00		

☒ No additional claim fees are required.

2. Extension of Time

☒ Applicant requests under the provisions of 37 CFR 1.136 (a) to extend the Period for filing a response in the above-identified application. The requested extension and appropriate non-small-entity fee are as follows:

Requested Extension	Large Entity Fee	Small-Entity Fee
<input checked="" type="checkbox"/> One month	\$120.00	\$60.00
<input type="checkbox"/> Two months	\$460.00	\$230.00
<input type="checkbox"/> Three months	\$1,050.00	\$525.00
<input type="checkbox"/> Four months	\$1,640.00	\$820.00
<input type="checkbox"/> Five months	\$2,230.00	\$1,115.00
Extension Fee Total		\$60.00

3. Terminal Disclaimer

☐ A Terminal Disclaimer is attached for which the appropriate fee is:

- ☐ Non Small-Entity \$130.00
- ☐ Small Entity \$65.00


4. Payment of Fees

The total of fees due under Sections 1-3, above, is \$60.00.

- ☐ A check in amount of the total of fees due is attached.
- ☒ Please charge \$60.00 to Deposit Account No. 23-1665. One additional copy of this transmittal is enclosed, if mailed.
- ☒ **Please charge any additional fees or credit overpayment to Deposit Account No. 23-1665.**

Respectfully submitted,
Jörgen Carlsson, et al.

Date: December 5, 2007


Elizabeth A. Galletta
Reg. No. 52,941

CONTACT INFORMATION:

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508-1832
Telephone: (203) 498-4345
Facsimile: (203) 782-2889
Email: egalletta@wiggin.com



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Patent Application : Jörgen Carlsson, et al.
Serial No. : 10/563,310
Filed : December 29, 2005
For : POLYPEPTIDES HAVING BINDING
AFFINITY FOR HER2

Examiner :
Attorney Docket : 102821-202
Group Art Unit :
Confirmation No. : 6946
Customer No. : 27267

* * * * *

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450 on December 5, 2007.

By

Elizabeth A. Galletta
Registration No. 52,941
Attorney for Applicants

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Dear Sir:

With respect to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed September 10, 2007, Applicants submit herewith a substitute sequence listing to correct errors noted by the Office. A paper copy of the

Filed December 29, 2005

sequence listing, as well as a computer readable form of the same, is enclosed herewith. Applicants submit the substitute sequence listing is in compliance with the requirements of 37 CFR §§ 1.822 and 1.823.

In the Notification, it was noted that Applicants' response for <213> was incorrect. In reply, Applicants submit herewith a copy of the sequence listing in paper and computer-readable form (CRF) with a response of "Artificial Sequence" for <213>. Additionally, per 37 CFR §1.823, the substituted sequence listing includes a response for <220>. Applicants submit the responses for <213> and <220> are in compliance with 37 CFR § 1.823. Accordingly, Applicants herein request the enclosed sequence listing be entered into the above-identified application.

Applicants state that with regard to the Sequence Listing, the information recorded in computer readable form is identical to the written sequence listing. Applicants submit no new matter is added herewith.

While Applicants believe no fee is currently due, Applicants authorize the Office to charge Deposit Account No. 23-1665 for any fees due with respect to this Response.


Filed December 29, 2005

A copy of the Notification is enclosed herewith.

If the Examiner believes a telephone conference would aid in the continued prosecution of this application, the Examiner is invited and encouraged to contact Applicants' representative at the telephone number listed below.

Respectfully submitted,


Jörgen Carlsson, et al.

By 
Elizabeth A. Galletta
Registration No. 52,941
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508
Telephone: (203) 498-4400
Fax: (203) 782-2889

Date: December 5, 2007

\\17451\\8\\57667.1




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/563,310	FIRST NAMED APPLICANT Jorgen Carlsson	ATTY. DOCKET NO. 102821-202
---	--	--------------------------------

27267
WIGGIN AND DANA LLP
ATTENTION: PATENT DOCKETING
ONE CENTURY TOWER, P.O. BOX 1832
NEW HAVEN, CT 06508-1832



INTERNATIONAL APPLICATION NO. PCT/SE04/01049	
I.A. FILING DATE 06/30/2004	PRIORITY DATE 07/04/2003

CONFIRMATION NO. 6946

371 FORMALITIES LETTER



OC000000025740593

Comply with Requirements due 11-10-07

Date Mailed: 09/10/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application** OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/563,310	PCT/SE04/01049	102821-202

FORM PCT/DO/EO/922 (371 Formalities Notice)